2018
Drug Resistance in HER2-Positive Breast Cancer Brain Metastases: Blame the Barrier or the Brain?
Kabraji S, Ni J, Lin NU, Xie S, Winer EP, Zhao JJ. Drug Resistance in HER2-Positive Breast Cancer Brain Metastases: Blame the Barrier or the Brain? Clinical Cancer Research 2018, 24: 1795-1804. PMID: 29437794, PMCID: PMC5899637, DOI: 10.1158/1078-0432.ccr-17-3351.Peer-Reviewed Original ResearchMeSH KeywordsAdaptation, PhysiologicalAnimalsAntineoplastic Combined Chemotherapy ProtocolsBlood-Brain BarrierBrain NeoplasmsBreast NeoplasmsClinical Studies as TopicDisease Models, AnimalDrug DevelopmentDrug Evaluation, PreclinicalDrug Resistance, NeoplasmFemaleHumansMiceModels, BiologicalReceptor, ErbB-2Translational Research, BiomedicalTreatment OutcomeXenograft Model Antitumor AssaysConceptsBreast cancer brain metastasesHER2-positive breast cancer brain metastasesTreatment of BCBMHER2-positive breast cancerHER2-targeting drugsInadequate drug penetrationBrain metastasis modelCancer brain metastasesCentral nervous systemClin Cancer ResDrug resistance mechanismsBrain metastasesFirst metastasisEffective therapyCommon siteBreast cancerMetastasis modelPharmacodynamic dataNervous systemTranslational research paradigmDrug penetrationCancer ResDrug sensitivityPatientsDrug development
2011
P4-11-10: Perceptions, Knowledge and Satisfaction with Contralateral Prophylactic Mastectomy among Young Women with Breast Cancer.
Tracy M, Meyer M, Sepucha K, Gelber S, Hirshfield-Bartek J, Troyan S, Morrow M, Schapira L, Come S, Winer E, Partridge A. P4-11-10: Perceptions, Knowledge and Satisfaction with Contralateral Prophylactic Mastectomy among Young Women with Breast Cancer. Cancer Research 2011, 71: p4-11-10-p4-11-10. DOI: 10.1158/0008-5472.sabcs11-p4-11-10.Peer-Reviewed Original ResearchContralateral prophylactic mastectomyContralateral breast cancerBreast cancerBilateral mastectomyYoung womenProphylactic mastectomyBenefits of CPMEarly breast cancerBilateral breast cancerSurgical treatment decisionsLongitudinal cohort studyBreast cancer treatmentPercent of womenCohort studyContralateral diseaseMedian ageProphylactic indicationsPatient preferencesTreatment decisionsMutation carriersAge 40MastectomyCancerCancer ResCancer treatmentP4-19-03: Physical and Psychological Sequelae of Breast Cancer in Men.
Ruddy K, Giobbie-Hurder A, Giordano S, Goldfarb S, Kereakoglow S, Winer E, Partridge A. P4-19-03: Physical and Psychological Sequelae of Breast Cancer in Men. Cancer Research 2011, 71: p4-19-03-p4-19-03. DOI: 10.1158/0008-5472.sabcs11-p4-19-03.Peer-Reviewed Original ResearchExpanded Prostate Cancer Index CompositeBreast cancerMale breast cancer survivorsSexual functioningProstate Cancer Index CompositeSupportive care needsCancer Therapy-BreastHealth-related qualityMale breast cancerBreast cancer survivorsHormonal symptomsFertility counselingCancer survivorsSexual symptomsHealth perceptionSubstantial symptomsDepression ScaleCare needsFunctional assessmentSymptomsLarger studyCancer ResHospitalized AnxietyPsychological sequelaeCancerPL1-1: How To Use Endocrine Therapy for Breast Cancer: Beyond the Basics.
Winer E. PL1-1: How To Use Endocrine Therapy for Breast Cancer: Beyond the Basics. Cancer Research 2011, 71: pl1-1-pl1-1. DOI: 10.1158/0008-5472.sabcs11-pl1-1.Peer-Reviewed Original ResearchHormone receptor-positive diseaseReceptor-positive diseaseEndocrine therapyPositive diseaseBreast cancerClinical practiceExtended adjuvant therapyAdjuvant endocrine therapyBreast cancer patientsAdjuvant therapyHormonal therapyMore treatment choicesPremenopausal womenSufficient therapyLate recurrenceCancer patientsAromatase inhibitorsTreatment choiceHigh riskPatientsTherapyDrug resistanceCancer ResHormone receptorsTumors
2009
Dose-dense (DD) doxorubicin and cyclophosphamide (AC) followed by weekly paclitaxel (P) with trastuzumab (T) and lapatinib (L) in HER2/neu-positive breast cancer is not feasible due to excessive diarrhea: updated results.
Dang C, Lin N, Moy B, Come S, Lake D, Theodoulou M, Troso-Sandoval T, Dickler M, Gorsky M, D'Andrea G, Modi S, Seidman A, Drullinsky P, Partridge A, Schapira L, Wulf G, Gilewski T, Atieh D, Mayer E, Isakoff S, Sugarman S, Fornier M, Traina T, Bromberg J, Currie V, Robson M, Burstein H, Overmoyer B, Ryan P, Kuter I, Younger J, Schumer S, Tung N, Zarwan C, Schnipper L, Chen C, Winer E, Norton L, Hudis C. Dose-dense (DD) doxorubicin and cyclophosphamide (AC) followed by weekly paclitaxel (P) with trastuzumab (T) and lapatinib (L) in HER2/neu-positive breast cancer is not feasible due to excessive diarrhea: updated results. Cancer Research 2009, 69: 2108. DOI: 10.1158/0008-5472.sabcs-2108.Peer-Reviewed Original ResearchDd ACHER2- BCLVEF declineDose reductionHER2/neu-positive breast cancerCongestive heart failure ratesNeu-positive breast cancerAsymptomatic LVEF declineCardiac event rateDose-dense doxorubicinHeart failure ratesDose delaysExcessive diarrheaWeekly paclitaxelMedian ageCardiac safetyMonth 2Breast cancerEvent ratesCancer ResDiarrheaPilot studyLVEFLapatinibBaseline